课题基金 / 基金详情

DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES

DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
多西尔
批准号：
6305818
负责人：
CAROLYN WASSERHEIT
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6305818
关键词：
clinical research clinical trial phase I combination cancer therapy dosage doxorubicin drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer relapse /recurrence paclitaxel pharmacokinetics

项目摘要

项目成果

CAROLYN WASSERHEIT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This phase I investigator-initiated trial is for patients who have confirmed malignancy for which an effective therapy is unavailable or was already used with disease recurrence in < one year. The objectives are to determine the maximal tolerated dose of Taxotere that can be administered in combination with Doxil at a fixed dose of 30 mg/m2 every 21 days. Dose-limiting toxicity, antitumor activity and pharmacokinetics will be also be determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXORUBICIN AND EDATREXATE IN THE TREATMENT OF SOLID TUMORS
海外基金